Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

Withdrawn before enrolling

Conditions studied: Amyloidosis, Paraproteinemias, Cardiomyopathies

In brief

Cardiac amyloidosis describes a process by which abnormally folded proteins infiltrate the heart tissue. Given the insidious nature of this disease process, diagnosis is often too late for a meaningful intervention. Advances in the treatment of the amyloidoses have improved outcomes for patients with these conditions. The focus of this study is to identify the involvement of the heart, most closely associated with mortality, so that aggressive management can be instituted improving prognosis.

Key facts

Study ID

NCT02462213

Run by

University of Cincinnati

People needed

0

Starts

2013-10-01

Expected to finish

2017-12-01

Last updated by the study team

2017-10-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects meeting diagnostic criteria for the target population will be recruited for the study. Age range will be 18 to 85 years of age.

You may not qualify if…

• Exclusion criteria will include history of heart transplantation as well as any contraindications for 1.5T CMR. For the use of GBCA, patients with acute renal failure or stage IV/V chronic renal failure will be excluded. Patients with end stage renal failure receiving peritoneal dialysis will also be excluded. Women who are pregnant or breast feeding will also be excluded.

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.